Skip to Main Content

Paper Details

Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial.
J Am Heart Assoc
0
2021
MACEs, Patients, Peripheral Artery Disease, TRA, Thrombin, Thrombin Receptor, Vorapaxar, limb ischemic, limb ischemic events, patients, peripheral artery disease, statin, thrombin, vorapaxar
Author NameAffiliation
David A MorrowCardiovascular Division Department of Medicine TIMI Study GroupBrigham and Women's Hospital and Harvard Medical School Boston MA.
David A MorrowCardiovascular Division Department of Medicine TIMI Study GroupBrigham and Women's Hospital and Harvard Medical School Boston MA.
Mark A CreagerDartmouth-Hitchcock Medical CenterHeart and Vascular Center Lebanon NH.
Mark A CreagerDartmouth-Hitchcock Medical CenterHeart and Vascular Center Lebanon NH.
Jeffrey W OlinZena and Michael A. Wiener Cardiovascular InstituteIcahn School of Medicine at Mount Sinai New York NY.
Benjamin M SciricaCardiovascular Division Department of Medicine TIMI Study GroupBrigham and Women's Hospital and Harvard Medical School Boston MA.
  • 1 - 6

Datasets

Release 1.2